The Massachusetts-based company's aptamer product candidates include ARC1779 for thrombotic microangiopathyies and carotid endarterectomy surgical procedure, as well as product candidates for cardiovascular, hematology, and oncology diseases. Archemix Corp. was founded in 2000 and is focused on developing innovative treatments for a range of diseases.